Use of and Barriers to Subcutaneous Apomorphine Pen Injections in Parkinson's Disease: A Survey by the French NS-PARK Network.
作者信息
Aubignat Mickael, Khelifi Fatma, Rascol Olivier
机构信息
Department of Neurology and Movement Disorders, Expert Center for Parkinson's Disease, NS-PARK Network, Amiens Picardie University Hospital, Amiens, France.
NS-PARK Network and Clinical Investigation Center CIC1436, INSERM, Toulouse, France.
出版信息
Mov Disord Clin Pract. 2025 Aug;12(8):1211-1213. doi: 10.1002/mdc3.70074. Epub 2025 Apr 9.
Abstract
摘要
相似文献
1
Use of and Barriers to Subcutaneous Apomorphine Pen Injections in Parkinson's Disease: A Survey by the French NS-PARK Network.
Mov Disord Clin Pract. 2025 Aug;12(8):1211-1213. doi: 10.1002/mdc3.70074. Epub 2025 Apr 9.
2
Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS-Park Cohort.
Mov Disord Clin Pract. 2025 Jul 17. doi: 10.1002/mdc3.70240.
3
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.
Neurol Ther. 2025 Jul 8. doi: 10.1007/s40120-025-00789-9.
4
Twenty-five-year experience with apomorphine pump in Parkinson's disease: A real-life long-term retrospective tolerance study.
J Parkinsons Dis. 2025 Aug;15(5):970-981. doi: 10.1177/1877718X251344896. Epub 2025 Jun 16.
5
Knowledge and utilization of compensation strategies for Parkinson's disease in Dutch long-term care facilities: A survey among 130 healthcare professionals.
J Parkinsons Dis. 2025 Jun 26:1877718X251354928. doi: 10.1177/1877718X251354928.
6
Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.
J Parkinsons Dis. 2025 Apr 29:1877718X251330993. doi: 10.1177/1877718X251330993.
7
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study.
J Parkinsons Dis. 2025 Mar;15(2):361-373. doi: 10.1177/1877718X241310727. Epub 2025 Jan 29.
8
Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
Clin Transl Sci. 2024 May;17(5):e13796. doi: 10.1111/cts.13796.
9
Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
Mov Disord Clin Pract. 2023 Jun 26;10(9):1253-1267. doi: 10.1002/mdc3.13810. eCollection 2023 Sep.
10
The Views of Healthcare Professionals on iFall, a Smartphone Application for Falls Reporting in Parkinson's Disease: A Qualitative Study.
J Geriatr Psychiatry Neurol. 2025 Feb 1;38(5):8919887251317728. doi: 10.1177/08919887251317728.
本文引用的文献
1
Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience.
Mov Disord Clin Pract. 2022 Oct 27;10(2):190-208. doi: 10.1002/mdc3.13593. eCollection 2023 Feb.
2
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Mov Disord. 2021 Oct;36(10):2244-2253. doi: 10.1002/mds.28726. Epub 2021 Aug 7.
3
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Lancet Neurol. 2020 Feb;19(2):135-144. doi: 10.1016/S1474-4422(19)30396-5. Epub 2019 Dec 7.
4
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
Arch Neurol. 2001 Sep;58(9):1385-92. doi: 10.1001/archneur.58.9.1385.
5
Apomorphine: an underutilized therapy for Parkinson's disease.
Mov Disord. 2000 Sep;15(5):789-94. doi: 10.1002/1531-8257(200009)15:5<789::aid-mds1005>3.0.co;2-h.
Zotero 插件